News Next gen psoriasis drugs show superiority to Stelara Guselkumab can also be used if older drug Stellara fails.
Views & Analysis Interview: Vas Narasimhan on Novartis' goal to lead in CAR-T... Novartis’ head of drug development talks about its stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions about safety, manufacturing and cost versus clinical value remain
Views & Analysis Orphan drugs will fuel pharma's future - and a pricing pushb... Evaluate predicts sales could approach $8bn if approved.
Events Partner Content Viral Safety - 25-27 April 2017 - Amserdam, The Netherlands Viral Safety conference
News EU green light for Novartis combo in lung cancer Tafinlar and Mekinist looks set for approval in BRAF V600 lung cancer
News Novartis' Zykadia gets fast first-line lung cancer review Roche rival has Breakthrough Therapy status.
News Cancer biotech Parabilis books record IPO, raising $670m Parabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
